LLY's Foundayo Just Proved Weight Loss Still Works in Menopause-Why That Matters Now

Foundayo menopause data broaden Lilly's obesity addressable market

At the ADA 86th Scientific Sessions earlier this month, Lilly reported that women in perimenopause taking Foundayo lost up to 14.4% of their body weight, while post-menopausal women lost up to 14.1%. Those results matter because menopause has often been viewed as a tougher group to treat: hormonal changes can accelerate abdominal fat and make weight loss harder to achieve and sustain. If Foundayo still delivers meaningful loss in this population, Lilly's obesity opportunity extends beyond the easiest-to-treat patients.